Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dexamethasone sodium phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate (AVM-0703) is under development for the treatment of type 1 diabetes, relapsed/refractory glioblastoma, metastatic breast cancer, metastatic ovarian cancer, metastatic gastric cancer, Hodgkin’s Lymphoma, leukemia, B-ALL, metastatic colon cancer, malignant myxoid spindle cell neoplasm, non-small cell lung cancer, desmoplastic small round cell tumor, metastatic esophageal adenocarcinoma, prostate cancer and diffuse large B-cell lymphoma arising from follicular lymphoma, primary diffuse large B-cell lymphoma of the CNS, high-grade B-cell lymphoma, Burkitt or Burkitt-like lymphoma/leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, T-cell lymphoma, or b-cell acute lymphoblastic leukemia, natural killer (NK) cell lymphoblastic leukemia/lymphoma and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), H1N1 influenza, influenza B. It is administered by intravenous route and acts by targeting glucocorticoid receptor (GR). The drug candidate acts by the producing gamma delta T cells. It was under development for the treatment of RSV infections.

AVM Biotechnology overview

AVM Biotechnology, formerly Ave Maria Biotechnology, is a biotechnology company. It discovers, develops and commercializes stem cell-enabling technologies for regenerative medicine, immuno-oncology and human biologics applications. The company’s lead product AVM0703 is a small molecule used to induce remission in refractory lymphocytic blood cancer and solid tumor patients as well as an immune reset therapy for autoimmune diseases includes multiple sclerosis and type 1 diabetes. Its AVM0703 is also used as a pre-conditioning agent for regenerative medicine with a variety of stem cell types for delaying malignant melanoma tumor growth. The company is also developing a precision medicine program for fully human biologics manufacturing. AVM Biotechnology is headquartered in Seattle, Washington, the US.

For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.